BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/15/2021 12:49:08 AM | Browse: 622 | Download: 1777
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 64343
Country Italy
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Saleh A Alqahtani and Massimo G Colombo
Funding Agency and Grant Number
Corresponding Author Massimo G Colombo, MD, Professor, Liver Center, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy. mcolombo46@yahoo.it
Key Words Hepatocellular carcinoma; Immune checkpoint inhibitor; Lenvatinib; Multi-tyrosine kinase inhibitor; Sorafenib
Core Tip Recently, an immunotherapy-based combination of atezolizumab and bevacizumab was shown to prolong survival compared to sorafenib in unresectable hepatocellular carcinoma (HCC) patients who did not receive prior therapy. In addition, the combination of lenvatinib and pembrolizumab has yielded promising results in the same patient setting. This review article summarizes the results obtained with sorafenib and lenvatinib in patients with unresectable HCC in pivotal clinical trials and real-world studies. We offer guidance on the optimal choice between sorafenib or lenvatinib in an individual patient and discuss the immunotherapy-based combination, which will likely make the choice between sorafenib and lenvatinib somewhat obsolete.
Publish Date 2021-12-14 23:58
Citation Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(12): 2038-2049
URL https://www.wjgnet.com/1948-5204/full/v13/i12/2038.htm
DOI https://dx.doi.org/10.4251/wjgo.v13.i12.2038
Full Article (PDF) WJGO-13-2038.pdf
Full Article (Word) WJGO-13-2038.docx